2026 Q2 -tulosraportti
30 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,98%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·29 min sittenSemaglutide may prove to have a much greater significance than just weight loss. Although the competition between new obesity medications often revolves around what percentage of body weight patients lose, the long-term health effects may ultimately be more important. CagriSema contains semaglutide, which is one of the most extensively studied drugs in metabolic disease. CagriSema must naturally document its own clinical results, but focusing on a few percentage points difference in weight loss may overlook semaglutide's potential broader benefits. Research points to possible positive effects on, among other things, cardiovascular disease, kidneys, liver, blood pressure, inflammation, physical function, and healthy aging. A new study in older, healthy mice is particularly interesting. Semaglutide increased the average lifespan from 742 to 834 days, corresponding to approximately 12.4%, along with improvements in several biological signs of aging and physical function. The results cannot be directly transferred to humans, and weight loss was part of the effect, but several of the benefits could not be explained solely by a lower caloric intake. There are also initial human data. At ADA 2026, Novo presented analyses suggesting that semaglutide can reduce biological age measured via proteins across multiple organs. More detailed scientific publications are expected later this year. Another exciting area is Alzheimer's disease. The ISAP study investigates whether one year of treatment with oral semaglutide can affect the accumulation of tau protein in the brain in people with amyloid changes, but without dementia. If semaglutide can actually slow tau accumulation, it could be a sign of a direct impact on a central biological process in Alzheimer's disease. For people with severe obesity, maximum weight loss effect will naturally continue to be very important. But for many other patients, the most important long-term questions may be: * Does the treatment reduce the risk of heart attack and stroke? * Does it protect kidneys and liver? * Does it help maintain physical function with age? * Can it affect biological aging? * Can it contribute to a longer and healthier life? The main point is therefore that the future competition between obesity medications may less be about who provides the greatest weight loss, and more about who provides the greatest long-term health benefits. So far, semaglutide has one of the broadest and most mature documentation bases within cardiovascular, renal, metabolic, and functional health effects.
·2 t sittenBe careful with recommendations from kim, 19, and her friend. She has admitted that she doesn't own novo shares here and yet she entices people to buy, so we just need kim to admit it too. Yesterday they thought it was close to 450 kr, so those they enticed to buy close to 310 are already in the red.If it's me you mean, I have very many, just not through Nordnet. What do you get out of that kind of harassment post?? By the way, I have said that it should find its way to 450, which is also not quite what you are writing here.
·8 t sittenNice rise in US 💰📈
- ·10 t sittenNovo Nordisk sees a fundamental change in the treatment of diabetes, obesity, and cardiovascular diseases. The focus is increasingly on organ protection and the prevention of long-term complications – not just on lowering blood sugar or reducing body weight. According to Henrik Jarlov, Vice President for Global Medical Affairs, Diabetes and Cardiovascular at Novo Nordisk, this development means that diabetes treatment, cardiology, nephrology, and obesity treatment are increasingly integrated around the individual patient. The goal is to choose treatments that can simultaneously reduce the risk of damage to the heart and kidneys, among other organs. Semaglutide is a central example of this development. Studies such as SUSTAIN 6, SELECT, and SOUL have shown cardiovascular benefits in various patient groups and with both injectable and oral formulations. Jarlov emphasizes, however, that the cardiovascular effects cannot automatically be considered a common effect for all GLP-1 treatments – each drug should be evaluated based on its own clinical documentation. An important point is that the cardiovascular benefits of semaglutide cannot necessarily be explained solely by weight loss. Data suggest that other mechanisms, including effects on blood pressure, inflammation, metabolic risk factors, and blood vessels, may also play a role. The future treatment of obesity is therefore also expected to become more individualized. For some patients, the greatest possible weight loss will be the most important goal, while others may benefit more from treatment focusing on, for example, organ protection, preservation of physical function, tolerability, or ease of use. This can be particularly relevant for elderly and frail patients, where a significant loss of muscle mass can be a concern. Novo Nordisk is simultaneously investigating new possibilities to reduce the so-called residual cardiovascular risk, partly through research into inflammation. Although the Phase 3 study ZEUS with ziltivekimab did not show a reduction in major cardiovascular events, the company continues other research programs in IL-6 inhibition. One of the biggest challenges in the coming years, however, will be to ensure that existing clinical evidence is actually translated into practice. Many patients who could potentially benefit from modern cardiometabolic treatments still do not receive them. The main message is therefore that the treatment goal is shifting: From primarily controlling blood sugar and weight to increasingly preventing damage to the heart, kidneys, and other organs – preferably before disease damage occurs.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
30 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,98%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·29 min sittenSemaglutide may prove to have a much greater significance than just weight loss. Although the competition between new obesity medications often revolves around what percentage of body weight patients lose, the long-term health effects may ultimately be more important. CagriSema contains semaglutide, which is one of the most extensively studied drugs in metabolic disease. CagriSema must naturally document its own clinical results, but focusing on a few percentage points difference in weight loss may overlook semaglutide's potential broader benefits. Research points to possible positive effects on, among other things, cardiovascular disease, kidneys, liver, blood pressure, inflammation, physical function, and healthy aging. A new study in older, healthy mice is particularly interesting. Semaglutide increased the average lifespan from 742 to 834 days, corresponding to approximately 12.4%, along with improvements in several biological signs of aging and physical function. The results cannot be directly transferred to humans, and weight loss was part of the effect, but several of the benefits could not be explained solely by a lower caloric intake. There are also initial human data. At ADA 2026, Novo presented analyses suggesting that semaglutide can reduce biological age measured via proteins across multiple organs. More detailed scientific publications are expected later this year. Another exciting area is Alzheimer's disease. The ISAP study investigates whether one year of treatment with oral semaglutide can affect the accumulation of tau protein in the brain in people with amyloid changes, but without dementia. If semaglutide can actually slow tau accumulation, it could be a sign of a direct impact on a central biological process in Alzheimer's disease. For people with severe obesity, maximum weight loss effect will naturally continue to be very important. But for many other patients, the most important long-term questions may be: * Does the treatment reduce the risk of heart attack and stroke? * Does it protect kidneys and liver? * Does it help maintain physical function with age? * Can it affect biological aging? * Can it contribute to a longer and healthier life? The main point is therefore that the future competition between obesity medications may less be about who provides the greatest weight loss, and more about who provides the greatest long-term health benefits. So far, semaglutide has one of the broadest and most mature documentation bases within cardiovascular, renal, metabolic, and functional health effects.
- ·2 t sittenBe careful with recommendations from kim, 19, and her friend. She has admitted that she doesn't own novo shares here and yet she entices people to buy, so we just need kim to admit it too. Yesterday they thought it was close to 450 kr, so those they enticed to buy close to 310 are already in the red.If it's me you mean, I have very many, just not through Nordnet. What do you get out of that kind of harassment post?? By the way, I have said that it should find its way to 450, which is also not quite what you are writing here.
- ·8 t sittenNice rise in US 💰📈
- ·10 t sittenNovo Nordisk sees a fundamental change in the treatment of diabetes, obesity, and cardiovascular diseases. The focus is increasingly on organ protection and the prevention of long-term complications – not just on lowering blood sugar or reducing body weight. According to Henrik Jarlov, Vice President for Global Medical Affairs, Diabetes and Cardiovascular at Novo Nordisk, this development means that diabetes treatment, cardiology, nephrology, and obesity treatment are increasingly integrated around the individual patient. The goal is to choose treatments that can simultaneously reduce the risk of damage to the heart and kidneys, among other organs. Semaglutide is a central example of this development. Studies such as SUSTAIN 6, SELECT, and SOUL have shown cardiovascular benefits in various patient groups and with both injectable and oral formulations. Jarlov emphasizes, however, that the cardiovascular effects cannot automatically be considered a common effect for all GLP-1 treatments – each drug should be evaluated based on its own clinical documentation. An important point is that the cardiovascular benefits of semaglutide cannot necessarily be explained solely by weight loss. Data suggest that other mechanisms, including effects on blood pressure, inflammation, metabolic risk factors, and blood vessels, may also play a role. The future treatment of obesity is therefore also expected to become more individualized. For some patients, the greatest possible weight loss will be the most important goal, while others may benefit more from treatment focusing on, for example, organ protection, preservation of physical function, tolerability, or ease of use. This can be particularly relevant for elderly and frail patients, where a significant loss of muscle mass can be a concern. Novo Nordisk is simultaneously investigating new possibilities to reduce the so-called residual cardiovascular risk, partly through research into inflammation. Although the Phase 3 study ZEUS with ziltivekimab did not show a reduction in major cardiovascular events, the company continues other research programs in IL-6 inhibition. One of the biggest challenges in the coming years, however, will be to ensure that existing clinical evidence is actually translated into practice. Many patients who could potentially benefit from modern cardiometabolic treatments still do not receive them. The main message is therefore that the treatment goal is shifting: From primarily controlling blood sugar and weight to increasingly preventing damage to the heart, kidneys, and other organs – preferably before disease damage occurs.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
30 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,98%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·29 min sittenSemaglutide may prove to have a much greater significance than just weight loss. Although the competition between new obesity medications often revolves around what percentage of body weight patients lose, the long-term health effects may ultimately be more important. CagriSema contains semaglutide, which is one of the most extensively studied drugs in metabolic disease. CagriSema must naturally document its own clinical results, but focusing on a few percentage points difference in weight loss may overlook semaglutide's potential broader benefits. Research points to possible positive effects on, among other things, cardiovascular disease, kidneys, liver, blood pressure, inflammation, physical function, and healthy aging. A new study in older, healthy mice is particularly interesting. Semaglutide increased the average lifespan from 742 to 834 days, corresponding to approximately 12.4%, along with improvements in several biological signs of aging and physical function. The results cannot be directly transferred to humans, and weight loss was part of the effect, but several of the benefits could not be explained solely by a lower caloric intake. There are also initial human data. At ADA 2026, Novo presented analyses suggesting that semaglutide can reduce biological age measured via proteins across multiple organs. More detailed scientific publications are expected later this year. Another exciting area is Alzheimer's disease. The ISAP study investigates whether one year of treatment with oral semaglutide can affect the accumulation of tau protein in the brain in people with amyloid changes, but without dementia. If semaglutide can actually slow tau accumulation, it could be a sign of a direct impact on a central biological process in Alzheimer's disease. For people with severe obesity, maximum weight loss effect will naturally continue to be very important. But for many other patients, the most important long-term questions may be: * Does the treatment reduce the risk of heart attack and stroke? * Does it protect kidneys and liver? * Does it help maintain physical function with age? * Can it affect biological aging? * Can it contribute to a longer and healthier life? The main point is therefore that the future competition between obesity medications may less be about who provides the greatest weight loss, and more about who provides the greatest long-term health benefits. So far, semaglutide has one of the broadest and most mature documentation bases within cardiovascular, renal, metabolic, and functional health effects.
- ·2 t sittenBe careful with recommendations from kim, 19, and her friend. She has admitted that she doesn't own novo shares here and yet she entices people to buy, so we just need kim to admit it too. Yesterday they thought it was close to 450 kr, so those they enticed to buy close to 310 are already in the red.If it's me you mean, I have very many, just not through Nordnet. What do you get out of that kind of harassment post?? By the way, I have said that it should find its way to 450, which is also not quite what you are writing here.
- ·8 t sittenNice rise in US 💰📈
- ·10 t sittenNovo Nordisk sees a fundamental change in the treatment of diabetes, obesity, and cardiovascular diseases. The focus is increasingly on organ protection and the prevention of long-term complications – not just on lowering blood sugar or reducing body weight. According to Henrik Jarlov, Vice President for Global Medical Affairs, Diabetes and Cardiovascular at Novo Nordisk, this development means that diabetes treatment, cardiology, nephrology, and obesity treatment are increasingly integrated around the individual patient. The goal is to choose treatments that can simultaneously reduce the risk of damage to the heart and kidneys, among other organs. Semaglutide is a central example of this development. Studies such as SUSTAIN 6, SELECT, and SOUL have shown cardiovascular benefits in various patient groups and with both injectable and oral formulations. Jarlov emphasizes, however, that the cardiovascular effects cannot automatically be considered a common effect for all GLP-1 treatments – each drug should be evaluated based on its own clinical documentation. An important point is that the cardiovascular benefits of semaglutide cannot necessarily be explained solely by weight loss. Data suggest that other mechanisms, including effects on blood pressure, inflammation, metabolic risk factors, and blood vessels, may also play a role. The future treatment of obesity is therefore also expected to become more individualized. For some patients, the greatest possible weight loss will be the most important goal, while others may benefit more from treatment focusing on, for example, organ protection, preservation of physical function, tolerability, or ease of use. This can be particularly relevant for elderly and frail patients, where a significant loss of muscle mass can be a concern. Novo Nordisk is simultaneously investigating new possibilities to reduce the so-called residual cardiovascular risk, partly through research into inflammation. Although the Phase 3 study ZEUS with ziltivekimab did not show a reduction in major cardiovascular events, the company continues other research programs in IL-6 inhibition. One of the biggest challenges in the coming years, however, will be to ensure that existing clinical evidence is actually translated into practice. Many patients who could potentially benefit from modern cardiometabolic treatments still do not receive them. The main message is therefore that the treatment goal is shifting: From primarily controlling blood sugar and weight to increasingly preventing damage to the heart, kidneys, and other organs – preferably before disease damage occurs.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt